Biodegradable Plastics Market

Report Code CH 2736
Published in Oct, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Biodegradable Plastics Market by Type (PLA, Starch Blends, PBAT, PHA, PBS, Cellulose Based), End-Use Industry (Packaging, Consumer Goods, Textiles, Agriculture & Horticulture), and Region- Global Forecast to 2029

Overview

The global biodegradable plastics market is estimated at USD 12.92 billion in 2024 and is projected to reach USD 33.52 billion by 2029, at a CAGR of 21.3% from 2024 to 2029. Rising awareness amongst the people related to environment coupled with the increasing demand for packaging end use industry in emerging economies is expected to drive the market during the forecast period. Furthermore, stringent traditional plastic regulations in the developed economies such as US, Europe and Japan are expected to significantly increase the demand for biodegradable plastics. The growing demand for biodegradable plastics is mainly due to the growing government focus on new policies related to use of traditional plastics and replacement with biodegradable plastics.

Attractive Opportunities in the Biodegradable Plastics Market

Asia Pacific

The availability of low-cost raw material and labor along with increasing demand from packaging, consumer goods, agriculture & horticulture end use industries in Asia Pacific can be attributed to the expansion of the application areas. Which is leading to increased demand for biodegradable plastics in the region.

The increasing application of biodegradable plastics in packaging end use industry is contributing to the growth of the market in Asia Pacific.

China having most of the production of biobased manufacturing market leading to growth in Asia Pacific region

The Asia Pacific biodegradable plastics market is expected to be worth USD 6.50 billion by 2029, growing at CAGR of 23.4% during the forecast period.

Easy availability of raw materials, low-cost labor, and improved lifestyle coupled with stringent plastics regulations are growth opportunities for biodegradable plastics market .

Global Biodegradable Plastics Market Dynamics

DRIVER: Growing demand of PHA in pharmaceuticals to boost the market growth

In the pharmaceutical sector, there is growing demand for biodegradable plastics, specifically Polyhydroxyalkanoates (PHA), owing to several compelling drivers. Such materials, based on renewable resources such as plant sugars and bacterial fermentation, represent an alternative to conventional petroleum-based plastics. PHA is an attractive solution because it degrades completely into non-toxic by-products in natural environments. Regulatory bodies, such as the European Union and the FDA, are increasingly promoting eco-friendly materials, which encourages pharmaceutical manufacturers to explore biodegradable alternatives for packaging, medical devices, and drug delivery systems.

Companies in the pharmaceutical industry have been challenged to be more sustainable. Many companies have included biodegradable plastics, PHA, in their production lines. They want to reduce carbon footprint and participate in circular economy programs. Renewable source material, minimal lifecycle, and environmental damage of PHA portray it as a vital material for companies to adapt towards corporate sustainability achievements. Due to the biocompatibility and nontoxicity of PHA, its use is valuable in pharmaceutical applications. Potential applications lie in drug encapsulation, controlled release drug delivery systems, and medical implants. Because of the biodegradable nature without creating side effects, it makes the material appropriate for the stated application. Additionally, its simple processibility into a wide range of forms such as films, coatings, and microparticles, expands its use across many pharmaceutical packaging and delivery systems.

RESTRAINT: Volatility in raw material prices

Raw material price volatilities might restrain market performance greatly as there would be an uncertainty that makes a difference with the profit margin of the concerned businesses. Here, it seems more restraining since raw materials are renewable resources, i.e., biodegradable and obtained from the natural sources of the plants and microorganisms. This mainly consists of corn, potato, cassava, and wheat starches, the most widely used mainly because of abundance and biodegradability. Cellulose from wood pulp, cotton, and hemp are another essential input, which helps in the production of biodegradable plastics such as cellulose acetate. The cost of these raw materials varies, and this has increased the cost of operations, making it difficult for companies to maintain competitive prices while controlling their costs. For instance, if the price of raw materials suddenly increases, it becomes hard to transfer such costs to consumers without affecting demand.

This has caused a squeeze on margins, in which the cost escalation occurs with falling sales prices. This thus threatens long-term profitability. Rapid changes in raw material prices can lead to inventory losses for biodegradable plastics manufacturing companies. When prices rise sharply, companies may not pass on the total cost increase to their customers, resulting in margin erosion. Conversely, companies may have to sell their existing inventory at lower prices when prices fall, leading to inventory losses.

 

OPPORTUNITY: PLGA to open new avenue in the pharmaceutical industry in biodegradable plastics market

Poly(lactic-co-glycolic acid), PLGA is an amorphous, biodegradable, and biocompatible copolymer of lactide and glycolide that has recently gained great interest in the pharmaceutical industry, having applications varying from controlled drug delivery. It is capable to degrade to nontoxic by-products like lactic and glycolic acid which are helpful in injectable formulation, drugs, and tissue engineering.

One of the major growing chances for PLGA is in its ability to deliver sustained, controlled release of APIs. Its degradation rate and drug release profile can be adjusted with the manipulation of the composition of the polymer. This made PLGA ideal for drugs requiring prolonged release: anticancer drugs, painkillers, and even hormone replacement therapy. Besides the delivery of drugs, it has been also making a pace in tissue engineering and regenerative medicine. Moreover, since the process of cell growth can be supported with gradual degradation, this macromolecule is greatly useful for scaffolds in tissue regeneration. Considering that the need for personalized medicine and long-acting injectable formulations increases, PLGA's scope in pharmaceuticals is going to expand significantly, giving better patient outcome and lesser interventions.

CHALLENGES: High price and complex production process

The bio-refinery process is one of the most expensive units in the biotechnological manufacturing sector. Very high capital investment is required to set up a bio-refinery, and most bio-products do not reach the economy of scale. Cheaper and more efficient products, such as petroleum products, are easily available in the market. Thus, the entire production process and its use is expensive. The production process of biodegradable plastics is complicated and poses various challenges that are limiting the growth of the market and its adoption. One of the main problems is the multi-step process of manufacturing biodegradable plastics, which involves several stages, including raw material sourcing, polymerization, and compounding. For example, the production of PLA involves some critical steps. First, the sugars must be fermented to obtain lactic acid, and then polymerized under specific conditions to obtain PLA. The process is very intricate and sensitive to variations because at each stage of the process, parameters such as temperature and pressure need to be controlled in order to achieve product quality.

Global Biodegradable Plastics Market Ecosystem Analysis

The biodegradable plastics ecosystem includes raw material suppliers, manufacturers, distributors, and end users. Some of the key biodegradable plastics manufacturers include NatureWork LLC (US), BASF SE (Germany), TotalEnergies Corbion (Netherlands), Mitsubishi Chemical Group Corporation. (Japan), Biome Bioplastics (UK), Plantic (Australia), FKuR (Germany), Danimer Scientific (US), TORAY INDUSTRIES, INC. (Japan), and Novamont (Italy). The biodegradable plastics ecosystem comprises raw material suppliers who supply chemicals to manufacturers; manufacturers who research & develop the final products for use in various industries, and intermediaries & distributors who provide a link between the manufacturers and end users by supplying the final products. They work together to supply the final products to end users in different industries. It involves a series of processes, beginning with raw material procurement from suppliers to manufacturing the end products and distributing them to end users for further use in various end-use industries.

 

Based on the End-use industry, the consumer goods end-use industry is estimated to be the second fastest growing end use industry during the forecast period.

The consumer goods end-use industry is estimated to be the second fastest growing end use industry during the forecast period. Major consumer goods falling under this category include electrical appliances, domestic appliances, etc. Major companies manufacturing consumer goods have now shifted towards developing biodegradable plastics instead of traditional plastics. Biodegradable plastics are producing consumer goods such as casings of touchscreen computers, speakers, mobile casings, and vacuum cleaners. Increasing environmental awareness among consumers led to their search for more environmentally sensitive products. Such consumers goods, therefore, would meet this need through incorporation of biodegradable plastics, thus helping increase their reputation on the market and attract an environmentally conscious consumer.

A large proportion of consumer electrical appliances are made of plastic. The consumer electrical appliances industry is extremely competitive, with new companies constantly entering the market and competing with major players like Apple, Samsung, and Sony. Biodegradable plastics can be used as an alternative to conventional plastics for the casing and housing of electrical appliances. Biodegradable plastics manufacture coffee pods, dinnerware, and many other consumer products used for household applications. Biodegradable housewares are becoming increasingly popular as advancements in bioplastics technology make them more durable, affordable, and environmentally friendly. Recent innovations include the use of PLA and polyhydroxy PHA to create items like cutlery, plates, storage containers, and utensils that naturally decompose under composting conditions.

Based on type, Starch blend type is expected to hold the second largest market share during the forecast period.

Starch blends are highly accepted in the market for biodegradable plastics due to their eco-friendly and versatile nature. Bioplastics derived from renewable sources such as corn, potatoes, and tapioca may offer sustainable alternatives for traditional plastics derived from petroleum. The potential applications of these bio-polymers can be enhanced by mixing starch with biodegradable polymers such as PLA or PHA. These bio-composites are biodegradable, they break into carbon dioxide, water, and biomass through microbial activity without damaging the environment significantly. Their degradation rates would be susceptible to temperature, moisture, and availability of enzymes for biodegradation and therefore amenable to industrial composting.

However, in home composting systems, they too have the potential for breaking under suitable conditions. Starch blends are used widely in packaging, agriculture, and consumer goods industries. In packaging, they are applied in the manufacturing of biodegradable films, bags, and containers. They can be applied in agriculture as mulch films and seedling pots that will decompose in soil without harmful residues. In consumer goods, starch blends are applied in disposable cutlery, plates, and personal care product packaging. Increasing demand for sustainable materials globally favors the use of starch blends for plastic waste reduction and the support of the circular economy. Their cost-effectiveness and compatibility with existing manufacturing technologies further support their growth, positioning them as a key player in the biodegradable plastics sector.

Asia Pacific will hold the third-largest market share during the forecast period.

Asia Pacific is the fastest-growing region globally, owing to economic growth in countries such as India, China, South Korea, Malaysia, and Australia. It is one of the leading consumers of biodegradable plastics globally and has witnessed exponential growth in the consumption of biodegradable plastics in recent years. The presence of highly populated countries, such as China and India, has benefited the biodegradable plastics market, owing to the increasing demand for applications such as packaging, consumer goods, agriculture & horticulture, textiles, and other end-use industries. China, India, Japan, and South Korea are among the world's most populous countries, and require biodegradable plastics for various purposes, consistently generating demand for the products.

Asia Pacific is attracting investors to set up production facilities because raw materials and labor are available at lower costs. It has witnessed significant growth in manufacturing activities due to low manufacturing costs and the support of local governments. Several international players have already set up manufacturing facilities in this region. The key factors driving market growth are an increase in R&D investments and high demand for biodegradable products in various end-use industries. Most of the production of the bio-based manufacturing market in the region is confined to China, Thailand, and Japan. Some of the major players in the region include Tianjin GreenBio Materials Co. (China), Tianan Biologic Materials Co. Ltd. (China), Mitsubishi Chemical Holding Corporation (Japan), and Indorama Ventures PCL (Thailand).

HIGHEST CAGR MARKET IN 2024-2029
INDIA FASTEST GROWING MARKET IN THE REGION

Recent Developments of Biodegradable Plastics Market

  • In November 2024, BASF SE launched an innovative midsole technology called CircleCELL in collaboration with Mount to Coast, a specialist in ultrarunning footwear. This midsole is the first to utilize BASF's new biomass-balanced ecoflex BMB biopolymer, which enhances performance while promoting sustainability. The CircleCELL midsole is reported to be 90% more durable than traditional materials like polyether block amide (PEBA), maintaining the same energy return essential for high-performance running shoes.
  • In November 2024, Toray Industries, Inc. had signed a memorandum of understanding with PTT Global Chemical Public Company Limited (GC) to explore mass production technology for adipic acid derived from non-edible biomass. The partnership was aimed to assess the feasibility of this technology and its commercialization in Thailand and Japan, with a goal of producing several thousand metric tons of bio-based muconic and adipic acid annually by 2030.
  • In September 2024, Danimer Scientific and Ningbo Homelink Eco-iTech had announced the commercial launch of a home compostable extrusion coating biopolymer based on polyhydroxyalkanoate (PHA). This innovative biopolymer, branded as Nodax, was designed to serve as a liquid barrier for paper cups, providing an alternative to traditional polyethylene coatings.
  • In April 2024, NatureWorks LLC has partnered with IMA Coffee to introduce a turn-key compostable coffee pod solution designed for compatibility with Keurig brewers in the North American market. This collaboration, which began in April 2021, leverages NatureWorks LLC ' expertise in Ingeo PLA biopolymer and IMA Coffee's proficiency in coffee processing and packaging technologies. The partnership aims to simplify the supply chain for coffee brands seeking sustainable packaging solutions that preserve the taste and aroma of coffee.

Key Market Players

KEY PLAYERS IN THE BIODEGRADABLE PLASTICS MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Biodegradable Plastics Market?

Scope of the Report

Report Metric Details
Years considered for the study 2021-2029
Base Year 2023
Forecast period 2024-2029
Units considered Value (USD Million), Volume (Kiloton)
Segments Type, End Use Industry, and Region
Region Asia Pacific, North America, Europe, Middle East & Africa, and South America

 

Key Questions Addressed by the Report

Which are the major companies in the biodegradable plastics market? What are their major strategies to strengthen their market presence?
Some of the key players in the biodegradable plastics market are NatureWork LLC (US), BASF SE (Germany), TotalEnergies Corbion (Netherlands), Mitsubishi Chemical Group Corporation (Japan), Biome Bioplastics (UK), Plantic (Australia), FKuR (Germany), Danimer Scientific (US), TORAY INDUSTRIES, INC. (Japan), and Novamont (Italy). Global companies offer high-quality biodegradable plastics and focus on developing a wide range for various applications. Local players are offering biodegradable plastics at lower costs to stay competitive in the market.
What are the drivers and opportunities for the biodegradable plastics market?
Government focus on new policies and regulations, the strong purchasing power of consumers, and a high degree of environmental awareness provide an opportunity for the market to grow.
Which region is expected to hold the highest market share?
Europe's biodegradable plastics market has been experiencing growth and significant industry demand. It is driven by economic growth in countries such as the UK, Germany, Italy, Spain, and France. The increasing demand from various end-use industries is driving the demand for biodegradable plastics in the region.
What is the total CAGR expected to be recorded for the biodegradable plastics market during 2024–2029?
The market is expected to record a CAGR of 25.5% during 2024–2029.
How is the biodegradable plastics market aligned?
The market has keen competition, and various growth strategies such as capacity expansion, mergers & acquisitions, and the launch of new products are planned by many manufacturers to maintain their presence in the market.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Biodegradable Plastics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
36
RESEARCH METHODOLOGY
42
EXECUTIVE SUMMARY
55
PREMIUM INSIGHTS
61
MARKET OVERVIEW
65
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing R&D investments in pharmaceutical and biotechnology industries
    - Growing adoption of biosimulation software by regulatory bodies
    - Integration of technologically advanced Quantitative Systems Pharmacology (QSP)
    - Need to curtail drug discovery and development costs
    - Growth in biologics and biosimilars markets
    RESTRAINTS
    - Lack of standardization
    - Data availability and quality
    OPPORTUNITIES
    - Emerging applications
    - Use of biosimulation solutions for pediatric drug development
    CHALLENGES
    - Difficulties in matching complexity of biological systems and processes
    - Shortage of biosimulation and modeling experts
  • 5.3 ECOSYSTEM ANALYSIS
    SOFTWARE PROVIDERS
    PHARMACEUTICAL & BIOTECH COMPANIES
    CONTRACT RESEARCH ORGANIZATIONS (CROS)
    REGULATORY BODIES
    ACADEMIC & RESEARCH INSTITUTIONS
  • 5.4 CASE STUDY ANALYSIS
    CASE STUDY 1: OPTIMIZING ASCIMINIB DEVELOPMENT THROUGH ADVANCED PBPK MODELING
    CASE STUDY 2: COMPUTATIONAL DISCOVERY OF SELECTIVE WEE1 INHIBITORS FOR CANCER
    CASE STUDY 3: EFFICIENT CLINICAL TRIAL UTILIZING SCALE MANAGEMENT EXPERTISE
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY ANALYSIS
    REGULATORY LANDSCAPE
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR BIOSIMULATION
    JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Mathematical modeling
    - Software platforms
    - Quantitative systems pharmacology (QSP)
    COMPLEMENTARY TECHNOLOGIES
    - Data analytics
    - Machine learning and AI
    ADJACENT TECHNOLOGIES
    - In silico trials
  • 5.10 INDUSTRY TRENDS
    DISCOVERY OF BIOMARKERS
    ADOPTION IN PERSONALIZED MEDICINE
  • 5.11 PRICING ANALYSIS
    INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING, 2023
    AVERAGE SELLING PRICE TREND, BY REGION (QUALITATIVE)
  • 5.12 KEY CONFERENCES & EVENTS, 2024–2025
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    BUYING CRITERIA
  • 5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.15 END-USER ANALYSIS
    UNMET NEEDS
    END-USER EXPECTATIONS
  • 5.16 INVESTMENT AND FUNDING SCENARIO
  • 5.17 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET
    KEY USE CASES
    IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    - Case study
    - Bioinformatics market
    - Drug discovery services market
    - Drug discovery informatics market
    USER READINESS & IMPACT ASSESSMENT
    - User readiness
    - Impact assessment
BIOSIMULATION MARKET, BY OFFERING
98
  • 6.1 INTRODUCTION
  • 6.2 SOFTWARE
    STANDALONE MODULES
    - Molecular modeling & simulation software
    - PK/PD modeling & simulation software
    - PBPK modeling & simulation software
    - Toxicity prediction software
    - Clinical trial simulation software
    - Other biosimulation software
    INTEGRATED SOFTWARE SUITES/PLATFORMS
    - Need for efficient R&D tools to accelerate growth of integrated platforms
  • 6.3 SERVICES
    CONSULTING & ADVISORY
    - Need to focus on core competencies to drive need for consulting & advisory services
    IMPLEMENTATION, TRAINING, AND SUPPORT
    - Need for well-trained professionals and experts to accelerate market growth
    DATA ANALYSIS & INTERPRETATION
    - Accurate and precise interpretation of data to drive need for data analysis & interpretation services
BIOSIMULATION MARKET, BY APPLICATION
114
  • 7.1 INTRODUCTION
  • 7.2 DRUG DISCOVERY
    TARGET IDENTIFICATION & VALIDATION
    - Need for identification of optimal targets in drug discovery to drive market
    LEAD IDENTIFICATION & OPTIMIZATION
    - Crucial role in facilitating viable drug discovery to accelerate  market growth
  • 7.3 DRUG DEVELOPMENT
    PRECLINICAL TESTING
    - PK/PD
    - ADME/Toxicology
    CLINICAL TRIALS
    - Phase I
    - Phase II
    - Phase III
    - Phase IV/Post-marketing surveillance
  • 7.4 DISEASE MODELING
    CAPABILITY TO PREDICT DISEASE DYNAMICS AND INFORM THERAPEUTIC STRATEGIES TO DRIVE MARKET GROWTH
  • 7.5 MANUFACTURING & SUPPLY CHAIN MANAGEMENT
    PRODUCTION PLANNING & OPTIMIZATION
    - Need for proper production planning and execution to drive market growth
    QUALITY CONTROL & PROCESS MONITORING
    - Adherence to maintaining product quality to fuel market growth
    DEMAND FORECASTING & INVENTORY MANAGEMENT
    - Need to forecast demand effectively to drive market growth
    RISK MANAGEMENT & CONTINGENCY PLANNING
    - Need to maintain operational continuity to support market growth
    OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS
  • 7.6 OTHER APPLICATIONS
BIOSIMULATION MARKET, BY THERAPEUTIC AREA
138
  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE MARKET GROWTH
  • 8.3 CARDIOVASCULAR DISEASES
    RISING NEED FOR DRUGS TO TREAT CARDIOVASCULAR DISEASES TO BOOST MARKET
  • 8.4 NEUROLOGICAL DISORDERS
    NEED TO BOOST DRUG DISCOVERY AND DEVELOPMENT FOR NEUROLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
  • 8.5 INFECTIOUS DISEASES
    RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY
  • 8.6 OTHER THERAPEUTIC AREAS
BIOSIMULATION MARKET, BY REVENUE MODEL
145
  • 9.1 INTRODUCTION
  • 9.2 LICENSE-BASED MODELS
    LICENSE-BASED MODELS TO ACCOUNT FOR LARGEST SHARE OF MARKET
  • 9.3 SUBSCRIPTION-BASED MODELS
    SUBSCRIPTION-BASED MODELS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 9.4 SERVICE-BASED MODELS
    SPECIALIZED SIMULATION EXPERTISE WITH SERVICE-BASED MODELS TO SUPPORT ADOPTION
  • 9.5 PAY-PER-USE MODELS
    RISING DEMAND FOR FLEXIBLE BIOSIMULATION SOLUTIONS WITHOUT UPFRONT COSTS TO SUPPORT MARKET GROWTH
BIOSIMULATION MARKET, BY DEPLOYMENT MODEL
151
  • 10.1 INTRODUCTION
  • 10.2 ON-PREMISE MODELS
    OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
  • 10.3 CLOUD-BASED MODELS
    CLOUD-BASED MODEL TO EXPERIENCE HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 10.4 HYBRID MODELS
    BALANCED CAPABILITIES OF HYBRID BIOSIMULATION MODELS TO ACCELERATE ADOPTION
BIOSIMULATION MARKET, BY END USER
156
  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
  • 11.3 CONTRACT RESEARCH ORGANIZATIONS
    RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
  • 11.4 ACADEMIC & RESEARCH INSTITUTES
    FAVORABLE GOVERNMENT SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
  • 11.5 REGULATORY BODIES
    GROWING USAGE OF BIOSIMULATION SOFTWARE FOR CLINICAL TRIAL EFFICACY TO PROPEL MARKET GROWTH
  • 11.6 OTHER END USERS
BIOSIMULATION MARKET, BY REGION
163
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Rising government funding for pharmaceutical R&D to drive market
    CANADA
    - Increasing funding by Canadian government in healthcare to drive market
  • 12.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - High number of sponsored clinical trials to drive uptake of biosimulation
    UK
    - Investments by pharmaceutical sponsors for drug discovery services to boost market
    FRANCE
    - Growing R&D pipeline for clinical trials to drive market
    ITALY
    - Increasing government funds and favorable regulatory scenarios to fuel uptake
    SPAIN
    - Established network of research centers to propel market
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Low cost of drug development and large pharmaceutical R&D base to drive market
    INDIA
    - Growing pharmaceutical industry to fuel uptake of biosimulation
    JAPAN
    - Established drug development infrastructure and biomedical research capabilities to support market growth
    REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Advancing biosimulation in region to support market growth
    MEXICO
    - Government initiatives to enhance digital health to propel market growth
    REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Increase in healthcare investments to support market growth
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
291
  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOSIMULATION MARKET
  • 13.3 REVENUE ANALYSIS, 2019–2023
  • 13.4 MARKET SHARE ANALYSIS, 2023
  • 13.5 RANKING OF KEY MARKET PLAYERS
  • 13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Offering footprint
    - Application footprint
    - End-user footprint
    - Region footprint
  • 13.7 COMPANY EVALUATION MATRIX: START-UP/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 13.8 COMPANY EVALUATION AND FINANCIAL METRICS, 2025
  • 13.9 BRAND/PRODUCT COMPARISON
  • 13.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & ENHANCEMENTS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
313
  • 14.1 KEY PLAYERS
    CERTARA, USA
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    DASSAULT SYSTÈMES
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    SCHRÖDINGER, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    SIMULATIONS PLUS
    - Business overview
    - Products & services offered
    - Recent Developments
    ADVANCED CHEMISTRY DEVELOPMENT, INC.
    - Business overview
    - Products & Services Offered
    - Recent developments
    CHEMICAL COMPUTING GROUP ULC
    - Business overview
    - Products & services offered
    - Recent developments
    ROSA & CO. LLC
    - Business overview
    - Products & services offered
    GENEDATA AG (A DANAHER COMPANY)
    - Business overview
    - Products & services offered
    - Recent developments
    PHYSIOMICS PLC
    - Business overview
    - Products & services offered
    - Recent developments
    IN SILICO BIOSCIENCES
    - Business overview
    - Products & services offered
    ALLUCENT
    - Business overview
    - Products & services offered
    - Recent developments
    OPENEYE, CADENCE MOLECULAR SCIENCES
    - Business overview
    - Products & services offered
    - Recent developments
    CELLWORKS GROUP, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    VERISIM LIFE
    - Business overview
    - Products & services offered
    - Recent developments
    NETABOLICS
    - Business overview
    - Products & services offered
    CHARNWOOD DISCOVERY
    - Business overview
    - Products & services offered
    - Recent developments
    THE MATHWORKS, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    ANSYS, INC.
    - Business overview
    - Products & services offered
    - Recent developments
  • 14.2 START-UP/SME PLAYERS
    INSTEM GROUP OF COMPANIES
    INSILICO MEDICINE
    SCM – SOFTWARE CHEMISTRY & MATERIALS
    BIOSYMETRICS, INC.
    ATOMWISE INC.
    INSITRO
    CLINITHINK
APPENDIX
376
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 BIOSIMULATION MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 2 BIOSIMULATION MARKET: PORTER’S FIVE FORCES
  • TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 4 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY OFFERING
  • TABLE 9 BIOSIMULATION MARKET: KEY CONFERENCES AND EVENTS, 2024–2025
  • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
  • TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • TABLE 12 UNMET NEEDS IN BIOSIMULATION MARKET
  • TABLE 13 END-USER EXPECTATIONS IN BIOSIMULATION MARKET
  • TABLE 14 BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 15 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 16 BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 17 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 18 BIOSIMULATION MARKET FOR STANDALONE MODULES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 19 BIOSIMULATION MARKET FOR MOLECULAR MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 20 BIOSIMULATION MARKET FOR PK/PD MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 21 BIOSIMULATION MARKET FOR PBPK MODELING & SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 22 BIOSIMULATION MARKET FOR TOXICITY PREDICTION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 23 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 BIOSIMULATION MARKET FOR OTHER BIOSIMULATION SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 BIOSIMULATION MARKET FOR INTEGRATED SOFTWARE SUITES/PLATFORMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 27 BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 28 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 32 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 33 BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 34 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION & OPTIMIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 37 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 BIOSIMULATION MARKET FOR ADME/TOXICOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 43 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 BIOSIMULATION MARKET FOR PHASE I CLINICAL TRIALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 BIOSIMULATION MARKET FOR PHASE II CLINICAL TRIALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 BIOSIMULATION MARKET FOR PHASE III CLINICAL TRIALS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 BIOSIMULATION MARKET FOR PHASE IV/POST-MARKETING SURVEILLANCE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 BIOSIMULATION MARKET FOR DISEASE MODELING APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 50 BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 BIOSIMULATION MARKET FOR PRODUCTION PLANNING & OPTIMIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 BIOSIMULATION MARKET FOR QUALITY CONTROL & PROCESS MONITORING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 BIOSIMULATION MARKET FOR DEMAND FORECASTING & INVENTORY MANAGEMENT, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 BIOSIMULATION MARKET FOR RISK MANAGEMENT & CONTINGENCY PLANNING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 BIOSIMULATION MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 58 BIOSIMULATION MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 64 BIOSIMULATION MARKET FOR LICENSE-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 BIOSIMULATION MARKET FOR SUBSCRIPTION-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 BIOSIMULATION MARKET FOR SERVICE-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 BIOSIMULATION MARKET FOR PAY-PER-USE MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 69 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 BIOSIMULATION MARKET FOR HYBRID MODELS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 72 BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 BIOSIMULATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 BIOSIMULATION MARKET FOR REGULATORY BODIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 BIOSIMULATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 81 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 83 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 87 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 88 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 94 US: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 95 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 96 US: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 97 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 98 US: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 99 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 100 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 101 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 102 US: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 103 US: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 104 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 105 US: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 106 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 107 US: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 108 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 110 CANADA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 111 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 112 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 113 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 114 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 115 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 116 CANADA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 117 CANADA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 118 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 119 CANADA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 120 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 121 CANADA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 122 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 124 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 125 EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 126 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 127 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 128 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 129 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 130 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 131 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 132 EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 133 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 134 EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 135 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 136 EUROPE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 137 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 138 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 139 GERMANY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 140 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 141 GERMANY: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 142 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 143 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 144 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 145 GERMANY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 146 GERMANY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 147 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 148 GERMANY: BIOSIMULATION MARKET, BY REVENUE MODEL,2022–2029 (USD MILLION)
  • TABLE 149 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 150 GERMANY: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 151 UK: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 152 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 153 UK: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 154 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 155 UK: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 156 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 157 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 158 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 159 UK: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 160 UK: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 161 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 162 UK: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 163 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 164 UK: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 165 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 166 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 167 FRANCE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 168 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 169 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 170 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 171 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 172 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 173 FRANCE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 174 FRANCE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 175 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 176 FRANCE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 177 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 178 FRANCE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 179 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 180 ITALY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 181 ITALY: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 182 ITALY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 183 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 184 ITALY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 185 ITALY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 186 ITALY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 187 ITALY: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 188 ITALY: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 189 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 190 ITALY: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 191 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 192 ITALY: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 193 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 194 SPAIN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 195 SPAIN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 196 SPAIN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 197 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 198 SPAIN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 199 SPAIN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 200 SPAIN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 201 SPAIN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 202 SPAIN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 203 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 204 SPAIN: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 205 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 206 SPAIN: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 207 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 208 REST OF EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 209 REST OF EUROPE: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 210 REST OF EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 211 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 212 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 213 REST OF EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 214 REST OF EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 215 REST OF EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 216 REST OF EUROPE: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 217 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 218 REST OF EUROPE: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 219 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 220 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 232 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 236 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 237 CHINA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 238 CHINA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 239 CHINA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 240 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 241 CHINA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 242 CHINA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 243 CHINA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 244 CHINA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 245 CHINA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 246 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 247 CHINA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 248 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 249 CHINA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 250 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 251 INDIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 INDIA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 253 INDIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 254 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 255 INDIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 256 INDIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 257 INDIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 258 INDIA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 259 INDIA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 260 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 261 INDIA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 262 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 263 INDIA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 264 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 265 JAPAN: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 JAPAN: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 267 JAPAN: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 268 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 269 JAPAN: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 270 JAPAN: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 271 JAPAN: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 272 JAPAN: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 273 JAPAN: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 274 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 275 JAPAN: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 276 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 277 JAPAN: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 278 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 280 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 281 REST OF ASIA PACIFIC: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 282 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 283 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 285 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 286 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 287 REST OF ASIA PACIFIC: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 288 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 289 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 290 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 291 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 292 LATIN AMERICA: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 293 LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 294 LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 295 LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 296 LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 297 LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 298 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 299 LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 300 LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 301 LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 302 LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 303 LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 304 LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 305 LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 306 LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 307 BRAZIL: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 308 BRAZIL: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 309 BRAZIL: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 310 BRAZIL: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 311 BRAZIL: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 312 BRAZIL: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 313 BRAZIL: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 314 BRAZIL: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 315 BRAZIL: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 BRAZIL: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 317 BRAZIL: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 318 BRAZIL: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 319 BRAZIL: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 320 BRAZIL: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 321 MEXICO: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 322 MEXICO: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 323 MEXICO: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 324 MEXICO: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 325 MEXICO: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 326 MEXICO: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 327 MEXICO: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 328 MEXICO: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 329 MEXICO: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 330 MEXICO: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 331 MEXICO: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 332 MEXICO: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 333 MEXICO: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 334 MEXICO: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 335 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 336 REST OF LATIN AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 337 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 338 REST OF LATIN AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE,2022–2029 (USD MILLION)
  • TABLE 339 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 340 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 341 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 342 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 343 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 344 REST OF LATIN AMERICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 345 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 346 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 347 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 348 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 349 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 350 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 351 MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 352 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 353 MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 354 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 355 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 356 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 357 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 358 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 359 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 360 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 361 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 362 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 363 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 364 GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 365 GCC COUNTRIES: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 366 GCC COUNTRIES: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 367 GCC COUNTRIES: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 368 GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 369 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 370 GCC COUNTRIES: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 GCC COUNTRIES: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 372 GCC COUNTRIES: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 373 GCC COUNTRIES: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 375 GCC COUNTRIES: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 376 GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 377 GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 378 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING, 2022–2029 (USD MILLION)
  • TABLE 379 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 380 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR STANDALONE MODULES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 381 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 382 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 383 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 384 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 385 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 386 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 387 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET FOR MANUFACTURING & SUPPLY CHAIN MANAGEMENT APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 388 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
  • TABLE 389 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY REVENUE MODEL, 2022–2029 (USD MILLION)
  • TABLE 390 REST OF MIDDLE EAST & AFRICA NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2022–2029 (USD MILLION)
  • TABLE 391 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 392 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET
  • TABLE 393 BIOSIMULATION MARKET: DEGREE OF COMPETITION
  • TABLE 394 BIOSIMULATION MARKET: OFFERING FOOTPRINT
  • TABLE 395 BIOSIMULATION MARKET: APPLICATION FOOTPRINT
  • TABLE 396 BIOSIMULATION MARKET: END-USER FOOTPRINT
  • TABLE 397 BIOSIMULATION MARKET: REGION FOOTPRINT
  • TABLE 398 BIOSIMULATION MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 399 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 400 BIOSIMULATION MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 401 BIOSIMULATION MARKET: DEALS, JANUARY 2021– JANUARY 2025
  • TABLE 402 BIOSIMULATION MARKET: EXPANSIONS, JANUARY 2021– JANUARY 2025
  • TABLE 403 BIOSIMULATION MARKET: OTHER DEVELOPMENTS, JANUARY 2021– JANUARY 2025
  • TABLE 404 CERTARA, USA: COMPANY OVERVIEW
  • TABLE 405 CERTARA, USA: PRODUCTS & SERVICES OFFERED
  • TABLE 406 CERTARA, USA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 407 CERTARA, USA: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 408 CERTARA, USA: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 409 DASSAULT SYSTÈMES: COMPANY OVERVIEW
  • TABLE 410 DASSAULT SYSTÈMES: PRODUCTS & SERVICES OFFERED
  • TABLE 411 DASSAULT SYSTÈMES: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021− JANUARY 2025
  • TABLE 412 DASSAULT SYSTÈMES: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 413 DASSAULT SYSTÈMES: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 414 SCHRÖDINGER, INC.: COMPANY OVERVIEW
  • TABLE 415 SCHRÖDINGER, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 416 SCHRÖDINGER, INC.: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 417 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 418 SIMULATIONS PLUS: COMPANY OVERVIEW
  • TABLE 419 SIMULATIONS PLUS: PRODUCTS & SERVICES OFFERED
  • TABLE 420 SIMULATIONS PLUS: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 421 SIMULATIONS PLUS: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 422 SIMULATIONS PLUS: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 423 ADVANCED CHEMISTRY DEVELOPMENT, INC.: COMPANY OVERVIEW
  • TABLE 424 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 425 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 426 ADVANCED CHEMISTRY DEVELOPMENT, INC.: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 427 CHEMICAL COMPUTING GROUP ULC: COMPANY OVERVIEW
  • TABLE 428 CHEMICAL COMPUTING GROUP ULC: PRODUCTS & SERVICES OFFERED
  • TABLE 429 CHEMICAL COMPUTING GROUP ULC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 430 CHEMICAL COMPUTING GROUP ULC: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 431 CHEMICAL COMPUTING GROUP ULC: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 432 ROSA & CO. LLC: COMPANY OVERVIEW
  • TABLE 433 ROSA & CO. LLC: PRODUCTS & SERVICES OFFERED
  • TABLE 434 GENEDATA AG (A DANAHER COMPANY): COMPANY OVERVIEW
  • TABLE 435 GENEDATA AG (A DANAHER COMPANY): PRODUCTS & SERVICES OFFERED
  • TABLE 436 GENEDATA AG (A DANAHER COMPANY): PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 437 GENEDATA AG (A DANAHER COMPANY): DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 438 PHYSIOMICS PLC: COMPANY OVERVIEW
  • TABLE 439 PHYSIOMICS PLC: PRODUCTS & SERVICES OFFERED
  • TABLE 440 PHYSIOMICS PLC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 441 PHYSIOMICS PLC: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 442 IN SILICO BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 443 IN SILICO BIOSCIENCES: PRODUCTS & SERVICES OFFERED
  • TABLE 444 ALLUCENT: COMPANY OVERVIEW
  • TABLE 445 ALLUCENT: PRODUCTS & SERVICES OFFERED
  • TABLE 446 ALLUCENT: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 447 ALLUCENT: EXPANSIONS, JANUARY 2021– JANUARY 2025
  • TABLE 448 ALLUCENT: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 449 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY OVERVIEW
  • TABLE 450 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCTS & SERVICES OFFERED
  • TABLE 451 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCT ENHANCEMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 452 OPENEYE, CADENCE MOLECULAR SCIENCES: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 453 OPENEYE, CADENCE MOLECULAR SCIENCES: EXPANSIONS, JANUARY 2021– JANUARY 2025
  • TABLE 454 CELLWORKS GROUP, INC.: COMPANY OVERVIEW
  • TABLE 455 CELLWORKS GROUP, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 456 CELLWORKS GROUP, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 457 VERISIM LIFE: COMPANY OVERVIEW
  • TABLE 458 VERISIM LIFE: PRODUCTS & SERVICES OFFERED
  • TABLE 459 VERISIM LIFE: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 460 VERISIM LIFE: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 461 NETABOLICS: COMPANY OVERVIEW
  • TABLE 462 NETABOLICS: PRODUCTS & SERVICES OFFERED
  • TABLE 463 CHARNWOOD DISCOVERY: COMPANY OVERVIEW
  • TABLE 464 CHARNWOOD DISCOVERY: PRODUCTS & SERVICES OFFERED
  • TABLE 465 CHARNWOOD DISCOVERY: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 466 THE MATHWORKS, INC.: COMPANY OVERVIEW
  • TABLE 467 THE MATHWORKS, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 468 THE MATHWORKS, INC.: PRODUCT ENHANCEMENTS, JANUARY 2021−JANUARY 2025
  • TABLE 469 ANSYS, INC.: COMPANY OVERVIEW
  • TABLE 470 ANSYS, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 471 ANSYS, INC.: DEALS, JANUARY 2021−JANUARY 2025
  • TABLE 472 ANSYS, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
LIST OF FIGURES
 
  • FIGURE 1 BIOSIMULATION MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 6 TOP-DOWN APPROACH
  • FIGURE 7 CAGR PROJECTIONS, 2024–2029
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 DATA TRIANGULATION
  • FIGURE 10 BIOSIMULATION MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 BIOSIMULATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 BIOSIMULATION MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 BIOSIMULATION MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 BIOSIMULATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 GEOGRAPHIC SNAPSHOT OF BIOSIMULATION MARKET
  • FIGURE 17 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
  • FIGURE 18 CHINA DOMINATED MARKET IN ASIA PACIFIC IN 2023
  • FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 20 NORTH AMERICA TO DOMINATE BIOSIMULATION MARKET DURING FORECAST PERIOD
  • FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 22 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 BIOSIMULATION MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 24 BIOSIMULATION MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 BIOSIMULATION MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 26 BIOSIMULATION-RELATED PATENT APPLICATIONS AND PUBLICATIONS, 2015–2024
  • FIGURE 27 BIOSIMULATION MARKET: PATENT ANALYSIS, JANUARY 2015–DECEMBER 2024
  • FIGURE 28 INDICATIVE PRICING ANALYSIS FOR BIOSIMULATION SOFTWARE
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS
  • FIGURE 30 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • FIGURE 31 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 32 BIOSIMULATION MARKET: INVESTMENT AND FUNDING SCENARIO FOR SMES
  • FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI ON BIOSIMULATION
  • FIGURE 34 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 35 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: BIOSIMULATION MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSIMULATION MARKET, 2019–2023 (USD BILLION)
  • FIGURE 38 BIOSIMULATION MARKET: MARKET SHARE ANALYSIS (2023)
  • FIGURE 39 RANKING OF KEY PLAYERS IN BIOSIMULATION MARKET, 2023
  • FIGURE 40 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 41 BIOSIMULATION MARKET: COMPANY FOOTPRINT
  • FIGURE 42 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • FIGURE 43 EV/EBITDA OF KEY VENDORS, 2025
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA VALUE FOR BIOSIMULATION VENDORS
  • FIGURE 45 BIOSIMULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 46 CERTARA, USA: COMPANY SNAPSHOT (2023)
  • FIGURE 47 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2023)
  • FIGURE 48 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 SIMULATIONS PLUS: COMPANY SNAPSHOT (2023)
  • FIGURE 50 GENEDATA AG (A DANAHER COMPANY): COMPANY SNAPSHOT (2023)
  • FIGURE 51 PHYSIOMICS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 52 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY SNAPSHOT (2023)
  • FIGURE 53 ANSYS, INC.: COMPANY SNAPSHOT (2023)

The study involved four major activities in estimating the market size of the biodegradable plastics market. Exhaustive secondary research was done to collect information on the market, the peer market, and the parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, the market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources have been referred to for identifying and collecting information for this study. These secondary sources include annual reports, press releases, investor presentations of companies, corporate documents, white papers, certified publications, trade directories, certified publications, articles from recognized authors, associations, gold standard and silver standard websites, and databases.

Secondary research has been used to obtain key information about the value chain of the industry, monetary chain of the market, the total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, and regional markets. It was also used to obtain information about the key developments from a market-oriented perspective.

Primary Research

The biodegradable plastics market comprises several stakeholders in the value chain, which include raw material suppliers, component manufacturers, manufacturers and end consumers. Various primary sources from the supply and demand sides of the biodegradable plastics market have been interviewed to obtain qualitative and quantitative information. The primary interviewees from the demand side include key opinion leaders in end-use sectors. The primary sources from the supply side include manufacturers, associations, and institutions involved in the biodegradable plastics industry.

Primary interviews were conducted to gather insights such as market statistics, data of revenue collected from the products and services, market breakdowns, market size estimations, market forecasting, and data triangulation. Primary research also helped in understanding the various trends related to type, end use industry and region. Stakeholders from the demand side, such as CIOs, CTOs, and CSOs were interviewed to understand the buyer’s perspective on the suppliers, products, component providers, and their current usage of biodegradable plastics and future outlook of their business which will affect the overall market.

The breakdown of profiles of the primary interviewees is illustrated in the figure below:

Note: Tier 1, Tier 2, and Tier 3 companies are classified based on their market revenue in 2023 available in the public domain, product portfolios, and geographical presence.

Other designations include sales representatives, production heads, and technicians.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The top-down approach was used to estimate and validate the size of various submarkets for biodegradable plastics for each region. The research methodology used to estimate the market size included the following steps:

  • The key players in the industry have been identified through extensive secondary research.
  • The supply chain of the industry has been determined through primary and secondary research.
  • The global market was then segmented into five major regions and validated by industry experts.
  • All percentage shares, splits, and breakdowns based on type, end use industry and region were determined using secondary sources and verified through primary sources.
  • All possible parameters that affect the markets covered in this research study were accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added with detailed inputs and analysis and presented in this report.

Source: Secondary Research, Interviews with Experts, and MarketsandMarkets Analysis

Data Triangulation

After arriving at the total market size from the estimation process of biodegradable plastics above, the overall market has been split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics for all the segments and sub-segments, the data triangulation and market breakdown procedures have been employed, wherever applicable. The data has been triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market size has been validated by using both the top-down and bottom-up approaches and primary interviews. Hence, for every data segment, there have been three sources—top-down approach, bottom-up approach, and expert interviews. The data was assumed correct when the values arrived from the three sources matched.

Market Definition

Biodegradable plastics are polymers that degrade naturally by the action of microorganisms, within a specified time under environmental conditions, such as composting or soil burial, into nontoxic by-products like water, carbon dioxide, or biomass. These plastics are produced from renewable sources like plant starches, cellulose, or even specifically designed petrochemicals, are designed to be less harmful and more environment-friendly compared with traditional plastics since they provide a greener substitute for plastics to resolve the problems of plastic wastes and pollution.

Stakeholders

  • Biodegradable plastics Manufacturers
  • Raw Material Suppliers
  • Manufacturing Technology Providers
  • Industry Associations
  • Manufacturers in End-Use Industries

Report Objectives

  • To define, describe, and forecast the size of the biodegradable plastics market, in terms of value and volume.
  • To provide detailed information regarding the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market.
  • To estimate and forecast the market size based on type, end use industry, and region.
  • To forecast the size of the market with respect to major regions, namely, Europe, North America, Asia Pacific, Middle East & Africa, and South America, along with their key countries.
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and their contribution to the overall market.
  • To analyze opportunities in the market for stakeholders and provide a competitive landscape of market leaders.
  • To track and analyze recent developments such as expansions, new product launches, partnerships & agreements, and acquisitions in the market.
  • To strategically profile key market players and comprehensively analyze their core competencies.

 

Previous Versions of this Report

Biodegradable Plastics Market by Type (PLA, Starch Blends, PHA, Biodegradable Polyesters), End Use Industry (Packaging, Consumer Goods, Textile, Agriculture & Horticulture), and Region( APAC, Europe, NA, South America, MEA) - Global Forecast to 2028

Report Code CH 2736
Published in Jul, 2023, By MarketsandMarkets™

Biodegradable Plastics Market by Type (PLA, Starch Blends, PHA, Biodegradable Polyesters), End Use Industry (Packaging, Consumer Goods, Textile, Agriculture & Horticulture), and Region (APAC, Europe, North America & RoW) - Global Forecast to 2026

Report Code CH 2736
Published in Sep, 2021, By MarketsandMarkets™

Biodegradable Plastics Market by Type (PLA, Starch Blends, Biodegradable Polyesters, PHA), End Use Industry (Packaging & Bags, Consumer Goods, Agriculture & Horticulture), and Region (APAC, Europe, North America, Rest of the World) - Global Forecast to 2023

Report Code CH 2736
Published in Oct, 2018, By MarketsandMarkets™

Biodegradable Plastics Market by Type (PLA, PHA, PBS, Starch-Based Plastics, Regenerated Cellulose, PCL), by Application (Packaging, Fibers, Agriculture, Injection Molding, and Others) - Global Trends & Forecasts to 2020

Report Code CH 2736
Published in Aug, 2015, By MarketsandMarkets™

Biodegradable Plastics Market by Type (PLA, PHA, PBS, Starch Based Plastics, Regenerated Cellulose, PCL), by Application (Packaging, Fibers, Agriculture, Injection Molding) - Global Trends and Forecasts to 2019

Report Code CH 2736
Published in Oct, 2014, By MarketsandMarkets™

Biodegradable Plastics Market by Type (PLA, PHA, PBS, Starch Based Plastics, Regenerated Cellulose, PCL), by Application (Packaging, Fibers, Agriculture, Injection Molding) - Global Trends and Forecasts to 2019

Report Code CH 2736
Published in Jan, 2011, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Biodegradable Plastics Market

DMCA.com Protection Status